Use of generic LC-MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody

Bioanalysis

Volumn 6, Issue 23, 2014, Pages 3225-3235

  Law, Wai Siang ^a,b   Genin, Jean Christophe ^a   Miess, Christian ^a   Treton, Gwenola ^a   Warren, Andrew Paul ^a   Lloyd, Peter ^a,c   Dudal, Sherri ^a,c   Krantz, Carsten ^a,d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ClinTec International AG   (Switzerland)

^c KinDyn Consulting LDT   (United Kingdom)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAB123; UNCLASSIFIED DRUG; LIGAND; MICROSPHERE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG MEGADOSE; FEMALE; IMMUNOAFFINITY CHROMATOGRAPHY; INTERMETHOD COMPARISON; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; NONHUMAN; QUALITY CONTROL; RECEPTOR BINDING ASSAY; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE; TANDEM MASS SPECTROMETRY; ANALYSIS; ANIMAL; HUMAN; MAGNET; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL;

ANALYTIC SAMPLE PREPARATION METHODS; ANIMALS; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; LIGANDS; LINEAR MODELS; MACACA FASCICULARIS; MAGNETS; MICROSPHERES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84919807836     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.167     Document Type: Article

References (40)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat. Biotech. 23(9), 1147-1157 (2005
2. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat. Rev Drug Discov. 5(2), 147-159 (2006
3. Weiner LM. Fully human therapeutic monoclonal antibodies. J. Immunother 29(1), 1-9 (2006
4. Zioncheck TF, Chen SA, Richardson L, et al. Pharmacokinetics and tissue distribution of recombinant human transforming growth-factor beta(1) after topical and intravenous administration in male-rats. Pharm. Res 11(2), 213-220 (1994
5. Desilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003
6. Lee JW, Kelley M, King LE, et al. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: Technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011
7. Li Hy, Ortiz R, Tran L, et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84(3), 1267-1273 (2012
8. Domon B, Aebersold R. Review - mass spectrometry and protein analysis. Science 312(5771), 212-217 (2006
9. Furlong MT, Ouyang Z, Wu S, et al. A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein Drug candidates in pre-clinical animal studies. Biomed. Chromatogr. 26(8), 1024-1032
10. Heudi O, Barteau S, Zimmer D, et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal. Chem. 80(11), 4200-4207 (2008
11. Hagman C, Ricke D, Ewert S, et al. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatographytandem mass spectrometry. Anal. Chem. 80(4), 1290-1296 (2008
12. Ji CJ, Sadagopan N, Zhang YZ, Lepsy C. A universal strategy for development of a method for absolute quantification of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra-performance liquid chromatography-Tandem mass spectrometry. Anal. Chem. 81(22), 9321-9328 (2009
13. Yang ZP, Hayes M, Fang XP, et al. LC-MS/MS approach therapeutic proteins for quantification of in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. Anal. Chem. 79(24), 9294-9301 (2007
14. Mire-Sluis AR, Barrett Yc, devanarayan v, et al. recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004
15. Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1-2), 1-9 (2008
16. Shankar G, Devanarayan V, Amaravadi L, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008
17. Wang SJ, Wu ST, Gokemeijer J, et al. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. Anal. Biol. Chem. 402(3), 1229-1239 (2012
18. Sailstad JM, Amaravadi L, Clements-Egan A, et al. A white paper-consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J. 1-11 (2014
19. Ji QC, Rodila R, Morgan SJ, et al. Investigation of the immunogenicity of a protein Drug using equilibrium dialysis and liquid chromatography tandem mass spectrometry detection. Anal. Chem. 77(17), 5529-5533 (2005
20. Kelley M, Ahene AB, Gorovits B, et al. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. AAPS J. 15(3), 646-658 (2013
21. Darwish IA, Al-Obaid ARM, Al-Malaq HAM. Preparation of a highly specific polyclonal antibody against fluvastatin and its use in Development of ELISA for determination of fluvastatin in plasma. Anal. Met. 1(3), 220-224 (2009
22. Stubenrauch K, Wessels U, Essig U, et al. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J. Pharm. Biomed. Anal. 52(2), 249-254 (2010
23. De Dios K, Manibusan A, Marsden R, et al. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin. J. Immunol. Methods 396(1-2), 1-7 (2013
24. Huang LH, Li JR, Wroblewski VJ, et al. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal. Chem. 77(5), 1432-1439 (2005
25. Tous GI, Wei ZP, Feng JH, et al. Characterization of a novel modification to monoclonal antibodies: Thioether cross-link of heavy and light chains. Anal. Chem. 77(9), 2675-2682 (2005
26. Yates JR. Mass spectrometry - from genomics to proteomics. Trends Genet. 16(1), 5-8 (2000
27. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: A tutorial. Mol. Syst. Biol. 4, 222 (2008
28. Mallick P, Kuster B. Proteomics: A pragmatic perspective. Nat. Biotech. 28(7), 695-709 (2010
29. Domon B, Aebersold R. Options and considerations when selecting a quantitative proteomics strategy. Nat. Biotech. 28(7), 710-721 (2010
30. Kiyonami R, Schoen A, Prakash A, et al. Increased selectivity, analytical precision, and throughput in targeted proteomics. Mol. Cell. Proteomics 10(2), M110002931 (2011
31. Wu SL, Amato H, Biringer R, et al. Targeted proteomics of low-level proteins in human plasma by LC/MSn: Using human growth hormone as a model system. J. Proteome Res. 1(5), 459-465 (2002
32. Nagele E, Vollmer M, Horth P, et al. 2D-LC/MS techniques for the identification of proteins in highly complex mixtures. Expert Rev. Proteomics 1(1), 37-46 (2004
33. Delahunty C, Yates JR. Protein Identification Using 2D-LC-MS/MS. Methods 35(3), 248-255 (2005
34. Taylor PJ. Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-electrospraytandem mass spectrometry. Clin. Biochem. 38(4), 328-334 (2005
35. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5(4), 573-588 (2006
36. Xu Y, Mehl JT, Bakhtiar R, et al. Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma. Anal. Chem. 82(16), 6877-6886 (2010
37. Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of lowabundance protein biomarkers. Expert Rev. Proteomics 4(2), 175-186 (2007
38. Knutsson M, Schmidt R, Timmerman P. LC-MS/MS of large molecules in a regulated bioanalytical environment - which acceptance criteria to apply? Bioanalysis 5(18), 2211-2214 (2013
39. Hotzel I, Theil FP, Bernstein LJ, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 4(6), 753-760 (2012
40. Deng R, Iyer S, Theil FP, et al. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. What have we learned? MAbs 3(1), 61-66 (2011